U.S. stock market midday update: AquaBounty Tech rises 17.86%

U.S. Stock Market Midday Update Stocks with High Trading Volume in the Industry Metsera rose 62.12%. Based on recent key news: On September 22, Pfizer announced it would acquire Metsera for $7.3 billion. This news significantly boosted Metsera's stock price, with an acquisition price of $47.50 per share, a 42.6% premium over last Friday's closing price. On September 22, Metsera's stock price soared 50% in pre-market trading, as the market anticipated that Pfizer's acquisition would enhance its competitiveness in the weight loss drug market. On September 22, Metsera's weight loss drug MET-233i is believed to potentially create a differentiated advantage in the market, further boosting investor confidence. The weight loss drug market is highly competitive, and risks should be monitored. Qualigen Therapeutics rose 92.68%. Based on recent important news: On September 22, Faraday Future announced a strategic investment in Qualigen Therapeutics totaling $41 million, facilitating its transformation into a crypto and Web3 platform. This move significantly increased Qualigen's stock price, with Faraday Future set to hold a substantial stake in Qualigen and planning to appoint a management team to lead new business activities. Source: IT Home. On September 22, Qualigen Therapeutics announced it would change its name to CXC10, focusing on the construction of the crypto and Web3 ecosystem, aiming to become a top U.S. listed company connecting Web2 and Web3. This news further propelled the stock price upward. Source: MyStonks. On September 20, Qualigen faced delisting pressure and underwent significant personnel changes. The CEO and CFO resigned, and the board quickly filled the vacancies. Although the personnel adjustments did not reverse the predicament, Faraday Future's investment introduced new variables for the company. Source: Company website. Investment in the crypto and Web3 sectors is active. AbbVie rose 1.03%, with a trading volume of $296 million. Based on recent key news: On September 20, AbbVie is conducting a Phase 1 study of a new drug GUB014295, and the research progress may impact the company's market performance in weight management. On September 19, significant breakthroughs in China's biopharmaceutical sector attracted collaborations from international pharmaceutical companies, with AbbVie signing multi-billion dollar licensing agreements with Chinese pharmaceutical firms. On September 22, despite AbbVie currently having a moderate buy rating among analysts, top analysts believe there are better investment options available. International collaboration in the biopharmaceutical industry is frequent, with innovative drugs on the rise. Stocks with High Market Capitalization in the Industry Amgen rose 0.42% according to recent key news: On September 19, Amgen's stock price increased by 2.3%, becoming the company with the largest gain among the Dow components. This rise was mainly driven by the market's positive response to its new drug Uplizna. On September 20, the European Medicines Agency's Committee for Medicinal Products for Human Use recommended expanding the indications for Uplizna to include the treatment of active immunoglobulin G4-related diseases. This news further propelled the stock price upward. On September 22, although analysts maintained a hold rating on Amgen, market confidence in its future growth strengthened, leading to a continued rise in the stock price. The biotechnology sector performed strongly overall